Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., . . . Winer, E. P. (2015). Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol.
শিকাগো স্টাইলে সাইটেশনSikov, William M., et al. "Impact of the Addition of Carboplatin And/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed By Dose-Dense Doxorubicin and Cyclophosphamide On Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)." J Clin Oncol 2015.
এমএলএ সাইটেশনSikov, William M., et al. "Impact of the Addition of Carboplatin And/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed By Dose-Dense Doxorubicin and Cyclophosphamide On Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)." J Clin Oncol 2015.